Prior to that he was Director at University College London as well as Director of Clinical Research at the UCL Institute of Child Health and Great Ormond Street Hospital for Children. He has raised over £50 million for clinical development programmes and was previously owner and CEO of a venture capital backed Clinical Research Organisation and a privately backed specialist Phase I CRO. As well as being a non-executive director of several life sciences companies, he has been senior independent director of one of the top performing NHS Foundation Trusts in England, a member of the clinical research panel for the UK’s Research Excellence Framework and is also chairman of Lord Snowdon’s Award Scheme for disabled students. Renny has a strong track history in the development and clinical investigation of new therapeutic assets. Over the last four years Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners. Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process. We look forward to continuing to work with the team at Aro in the search for novel Centyrins TM with high therapeutic potential in oncology and immunology”. The rapid screening via CIS display of multiple large libraries with different antigen binding surfaces has already enabled discovery of high affinity Centyrins TM that bind to a diversity of unique epitopes on target proteins, and that do not require affinity maturation.ĭr Adam Collier, Isogenica’s Director of Business Development commented: “it is very satisfying to see that the success of the first six months of this collaboration has resulted in this strengthening of the relationship. Under the expanded agreement, Isogenica will use its CIS Display platform to help Aro achieve its goal of developing novel Centyrins TM against multiple targets for cell – specific delivery.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |